Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00369122 | Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 2 | Mar 20, 2018 | clinicaltrials |
| NCT01005329 | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 3 | Mar 15, 2018 |
| clinicaltrials |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
| NCT00443196 | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas | completed | Phase 2 / Phase 3 | 150 | Pierian BiosciencesINDUSTRY | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01585428 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2018 | clinicaltrials |
| NCT01210222 | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Feb 23, 2018 | clinicaltrials |
| NCT02949791 | HIPEC Using High Intra-abdominal Pressure(HIPEC-IAP) | completed | Phase 2 | 38 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00257816 | Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma | completed | Phase 2 | 12 | University of California, IrvineOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01188876 | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00499252 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT01118052 | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00041093 | Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00691301 | Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | completed | Phase 2 | 55 | Gynecologic Oncology GroupNETWORK | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00820898 | Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 24 | Gynecologic Oncology GroupNETWORK | 1 | Dec 29, 2017 | clinicaltrials |
| NCT01276730 | Advanced Cervical Cancer Trial in India | completed | Phase 2 | 209 | University of LouisvilleOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT00258362 | Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer | completed | Phase 2 | 41 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00381888 | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer | completed | Phase 2 | 44 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00610740 | CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer | completed | Phase 2 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00617188 | Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer | completed | Phase 2 | 26 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01105650 | Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | completed | Phase 2 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00908960 | Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles(MicroTEC) | completed | Phase 2 | 70 | Beth Israel Deaconess Medical CenterOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT01617629 | Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study(CAN-003X) | completed | Phase 2 | 9 | Prima BioMed LtdINDUSTRY | 2 | Dec 8, 2017 | clinicaltrials |
| NCT00888173 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Dec 6, 2017 | clinicaltrials |
| NCT02454036 | Biobehavioral Intervention in Gynecologic Oncology Patients | completed | Phase 2 | 6 | Rachel MillerOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00334893 | Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00470366 | Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors | completed | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00068406 | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva | completed | Phase 2 | 61 | Gynecologic Oncology GroupNETWORK | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00941070 | Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00937560 | A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 9 | Nov 6, 2017 | clinicaltrials |
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Oct 9, 2017 | clinicaltrials |
| NCT03293628 | Comparing Two Techniques of Haemostasis After Cervical Conization | completed | Phase 2 | 100 | Barretos Cancer HospitalOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT00081263 | Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia | completed | Phase 2 | 130 | Gynecologic Oncology GroupNETWORK | 1 | Sep 15, 2017 | clinicaltrials |
| NCT00857545 | OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission | completed | Phase 2 | 171 | Gynecologic Oncology GroupNETWORK | 1 | Sep 13, 2017 | clinicaltrials |
| NCT01039207 | Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Sep 7, 2017 | clinicaltrials |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT00039442 | Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 21 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00521118 | Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors | completed | Phase 2 | 64 | Gynecologic Oncology GroupNETWORK | 2 | Aug 24, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00408603 | Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer | completed | Phase 2 | 183 | Sunesis PharmaceuticalsINDUSTRY | 2 | Jul 27, 2017 | clinicaltrials |
| NCT00856791 | Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients | completed | Phase 2 | 1 | Traws Pharma, Inc.INDUSTRY | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01905163 | Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients(CILOVE) | completed | Phase 2 | 47 | Centre Jean PerrinOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00045682 | CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 78 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00054119 | Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT02139267 | Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia | completed | Phase 2 | 72 | Genexine, Inc.INDUSTRY | 1 | Jul 12, 2017 | clinicaltrials |
| NCT00332033 | Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids) | completed | Phase 2 | 32 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00511992 | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | completed | Phase 2 | 20 | University of OklahomaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02130323 | Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix | completed | Phase 2 / Phase 3 | 22 | United States Naval Medical Center, San DiegoFED | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00061308 | Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer | completed | Phase 2 | 75 | GlaxoSmithKlineINDUSTRY | 2 | Jun 9, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2018source: clinicaltrials